Intended use:

The SeraSpot® Anti-Treponema-4 IgG / SeraSpot® Anti-Treponema-4 IgM is an in vitro diagnostic device (spotimmunoassay, SIA) for the detection of Treponema pallidum-specific IgG or IgM antibodies in human serum or plasma samples. The test can be used as a confirmatory test after a positive or a questionable result of a syphilis screening test (TPHATPPA-or TPLA-test).

General information:

Treponema pallidum ssp. pallidum is the causative agent of Syphilis, a sexually transmitted globally spread disease in humans. The clinical course of Syphilis is characterized by different stages with varying symptoms. Infection occurs by sexual contacts. Skin lesions but also intact mucosa in the genital, oral or anal region are the most likely sites of entry for the pathogen and from there it spreads via blood and lymph vessels. During this primary stage a painless ulcus (ulcus durum) develops at the site of entry and a swelling of the regional lymph nodes (lymphadenopathy). Without treatment the infection will enter into the secondary stage after 9-10 weeks. Clinical signs are patchy papular exanthema or other ulcerative skin irritations, accompanied by several less characteristic symptoms like lymphadenopathy, fatigue, weight loss, subfebrile temperatures etc. The papular skin rashes contain a large number of pathogens. In the course of the secondary stage, which lasts between weeks to months, specific antibodies are produced. Nevertheless reinfections may occur. After decline of the symptoms and a latency period of up to several years the tertiary stage with a wide range of symptoms depending on the respective organ manifestations develops. Involvement of the central nervous system results in the clinical picture of Neurosyphilis or other neurological manifestations (1, 2).

Treponema pallidum infections are diagnosed either by direct (pathogen detection or PCR) or indirect (serology) methods.

Test principle:

The SeraSpot® Anti-Treponema-4 IgG / SeraSpot® Anti-Treponema-4 IgM is a solid phase immunoassay based on the use of recombinant Treponema antigens as capture antigens printed in array arrangement (spot array) on the bottom of the wells of 96 well-microtiter plates. The recombinant antigens serve as capture molecules for antibodies against Treponema antigens. Bound antibodies are detected by Horseradish Peroxidase-(HRP)-labeled antibodies against human

antibodies of IgG- or IgM-type by substrate reaction with hydrogen peroxide and 3,3’,5,5’- Tetramethylbenzidine (TMB). At the site of formed immune complexes blue spots are developed by precipitated product from colorless substrate solution. Color intensity is correlated to the antibody concentration. Pale blue to dark blue spots are visible by eye.

Art. No.:

  • IgG antibodies: SP-010-4 G-S6 (1×48) / SP-010-4 G-S12 (1×96)
  • IgM antibodies: SP-010-4 M-S6 (1×48) / SP-010-4 M-S12 (1×96)

Art. No. SP-010-4 ****
Test format Microspot array
Incubation time 1.5 h

Dear customers,

we have started to provide the documents for our products in an electronic format. These are the Instructions for Use (IFU), the Safety Data Sheets (SDS) and the Certificate of Analysis (CoA). For batches placed on the market after 01 January 2023, you can find our documents on the eIFU portal

Similar products
SeraSpot® Anti-Treponema-4 IgG / IgM
SeraSpot® Anti-Treponema-4 ...
The SeraSpot® Anti-Treponema-4 IgG / SeraSpot® Anti-Treponema-4 IgM is an in vitro diagnostic device (spotimmunoassay, SIA) for the detection of Tr...
RIDA®GENE STI Mycoplasma Panel
RIDA®GENE STI Mycoplasma Panel
For in-vitro diagnostic use. RIDA®GENE STI Mycoplasma Panel is a multiplex real-time PCR for the direct, qualitative detection of Mycoplasma homini...
For in vitro diagnostic use. The RIDA®UNITY EHEC/EPEC test, performed on the RIDA®UNITY platform, is a multiplex real-time PCR for the direct quali...

Start typing and press Enter to search